Prevention of diabetes mellitus
"diabetes mellitus" AND "prevention"
prevention of diabetes mellitus type 2 guidelines 2025
"type 2 diabetes" AND "prevention" AND "lifestyle intervention"
| Parameter | Prediabetes Range |
|---|---|
| Fasting glucose | 100-125 mg/dL (IFG) |
| 2-hour post-glucose challenge | 140-199 mg/dL (IGT) |
| HbA1c | 5.7-6.4% |
| Drug | Evidence | Notes |
|---|---|---|
| Metformin | 31% RRR in DPP; IDPP-1 also confirmed benefit | ADA recommends considering in: BMI >35, age <60, history of GDM, progressive hyperglycemia despite lifestyle |
| Acarbose | Reduces IGT progression (STOP-NIDDM trial) | GI side effects limit use; ADA does not recommend routinely |
| Pioglitazone | Reduces T2DM risk in IGT | ACTnow trial; risk of weight gain, heart failure, fractures |
| Orlistat | Modest T2DM prevention (XENDOS trial) | ADA does not recommend routinely |
| Liraglutide | Reduces progression from prediabetes | ADA does not currently recommend routinely |
| Phentermine/topiramate ER | 10% weight loss reduces incident diabetes by 79% at 2 years | Under obesity indication |
| Level | Target | Approach |
|---|---|---|
| Primary | Inhibit development of islet autoimmunity | Dietary/environmental interventions (mostly investigational) |
| Secondary | Halt autoimmune processes; delay clinical onset in multi-autoantibody-positive individuals | Teplizumab (anti-CD3 monoclonal antibody): a 14-day course delays onset by ~2 years in high-risk relatives |
| Tertiary | Slow beta-cell destruction after T1DM diagnosis; prevent complications | Intensive glycemic control, teplizumab trials |
PREDIABETES IDENTIFIED
│
├── Lifestyle modification (FIRST LINE)
│ ├── 7-10% weight loss
│ ├── ≥150 min/wk moderate exercise
│ └── Dietary modification
│
├── Pharmacotherapy (if lifestyle insufficient)
│ ├── Metformin (ADA-endorsed)
│ └── Others (pioglitazone, acarbose - not routinely recommended)
│
├── CV risk factor management
│ ├── BP, LDL, smoking
│
└── Annual monitoring
Vision 2020 right to sight
Vision 2020 Right to Sight WHO IAPB global initiative objectives strategies
https://pmc.ncbi.nlm.nih.gov/articles/PMC1706008
Vision 2020 India NPCB national programme control blindness implementation results
"To eliminate the main causes of blindness in order to give all the people of the world, particularly the millions of needlessly blind, the Right to Sight by the year 2020."
| Disease | Key Intervention |
|---|---|
| Cataract | Surgical removal (IOL implantation); most common cause of avoidable blindness globally (43% in LMICs) |
| Trachoma | SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) |
| Onchocerciasis (River Blindness) | Ivermectin distribution (community-directed treatment) |
| Childhood blindness | Vitamin A supplementation, treatment of xerophthalmia, rubella vaccination, ROP screening |
| Refractive errors and Low vision | Refraction services, provision of spectacles, low vision devices |
| Corneal blindness | Keratoplasty, trachoma control |
| Glaucoma | Early detection and treatment |
| Diabetic retinopathy | Screening, laser therapy |

| Level | Number | Functions |
|---|---|---|
| Vision Centres (Primary) | 20,000 | Refraction and prescription of glasses, primary eye care, school eye screening, screening and referral |
| Service Centres (Secondary) | 2,000 | Cataract surgery, other common eye surgeries, refraction facilities, referral services |
| Training Centres (Tertiary) | 200 | Tertiary care (retinal surgery, corneal transplantation, glaucoma surgery), training and CME |
| Centres of Excellence (Tertiary) | 20 | Professional leadership, strategy development, CME, quality assurance, research |
| Feature | Details |
|---|---|
| Launch date | 18 February 1999 |
| Launched by | WHO + IAPB |
| Goal | Eliminate avoidable blindness by 2020 |
| Key concept | Sight as a fundamental human right |
| 3 core strategies | Disease control, Human resource development, Infrastructure & technology |
| Priority diseases | Cataract, Trachoma, Onchocerciasis, Childhood blindness, Refractive errors, Low vision |
| India's prevalence target | Reduce blindness from 1.4% to 0.3% |
| India's four-tier structure | Vision Centres (20,000) → Service Centres (2,000) → Training Centres (200) → Centres of Excellence (20) |
| Successor | Universal Eye Health Global Action Plan 2014-2019; "2030 in Sight" |